Scolipede

Boundaries Crossed · #74 · Rare Holo

Reference NM

€3.37

External reference · raw NM

PSA 9

€84.81

USD source

PSA 10

€101.44

USD source

Composite

4.7

Live raw NM price unavailable from primary source — showing external reference.

Cardmarket (EUR) →eBay (US) →

Buy range€2.22 – €2.91At market

All prices and projections are for Near Mint English-language cards. Other conditions and languages may vary significantly.

Price history

Ungraded NM PSA 9 PSA 10

Investment thesis

Sub-score breakdown · ROI projections

4.7

SCORE / 10

Liquidity

8.1

Scarcity

10.0

Era potential

3.3

Friction

6.3

Hold-Raw · 5Y Outlook▲ PRIMARY

+•••%

Available with Pro

Grade or sell · per-card

Free account

See if grading this card pays.

How is this scored?

The composite score (0–10) blends signals across trust, set tier, era, liquidity, and price. The four sub-scores shown above (Liquidity, Scarcity, Era CAGR, Friction) describe each card across complementary axes; they share inputs with the composite but use different formulas. The Friction sub-score (added 2026-05-11) combines liquidity, price-spread stability, era maturity, and affordability minus a flat marketplace-fee proxy. The era-benchmark ROI numbers project returns based on the card's release era — they're not card-specific predictions. Limitations: the score is a relative ranking heuristic, not a forecast. Prices are snapshots and can drift between refreshes — always verify externally before buying.

Pop report

PSA 10 gem rate 16.67%Total population

PSA 10

PSA 9

PSA 8

Total graded

Gem rate 16.67%. Consistent with modern era gem rates; expect supply to grow as more are graded.

OVERVIEW

Investment summary

Scolipede (#74) from Boundaries Crossed currently trades at €3.37 in the raw market. Over the past 30 days the card has declined -2.6%. By market value it ranks #28 of 153 in Boundaries Crossed — the 80th percentile of the set. With recent sales tracked over the trailing 180 days, liquidity is rated medium. Read together, a upper-tier ranking in Boundaries Crossed alongside softening 30-day momentum frames where Scolipede sits in the set's pricing structure — context worth weighing against the set's stronger names before timing an entry. Market data is informational only and does not constitute investment advice.